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STEATOHEPATITIS/METABOLIC LIVER DISEASE
Specific Immunization Strategies Against Oxidized Low-
Density Lipoprotein: A Novel Way to Reduce
Nonalcoholic Steatohepatitis in Mice
Veerle Bieghs,1 Patrick J. van Gorp,1 Sofie M.A. Walenbergh,1 Marion J. Gijbels,1,2 Fons Verheyen,3
Wim A. Buurman,4 David E. Briles,5,6 Marten H. Hofker,7 Christoph J. Binder,8,9 and Ronit Shiri-Sverdlov1
Nonalcoholic steatohepatitis (NASH) is characterized by hepatic lipid accumulation com-
bined with inflammation, which can ultimately progress into cirrhosis. Recently, we dem-
onstrated that deletion of scavenger receptors (SRs) CD36 and SR-A in hematopoietic
cells reduced hepatic inflammation. In addition to uptake of modified lipoproteins, CD36
and SR-A are also involved in other functions that can activate the inflammatory response.
Therefore, the actual trigger for SR activation during NASH is unclear. Here, we hypothe-
sized that hepatic inflammation is triggered by recognition of oxidized LDL (oxLDL) by
Kupffer cells (KCs). To inhibit recognition of oxLDL by KCs, low-density lipoprotein
receptor (Ldlr2/2) mice were immunized with heat-inactivated pneumococci, which were
shown to induce the production of anti-oxLDL immunoglobulin M (IgM) antibodies, due
to molecular mimicry with oxLDL. The mice received a high-fat, high-cholesterol diet dur-
ing the last 3 weeks to induce NASH. Immunization with pneumococci increased anti-
oxLDL IgM levels and led to a reduction in hepatic inflammation, as shown by reduced
macrophage, neutrophil, and T cell infiltration, and reduced gene expression of tumor
necrosis factor (Tnf ), interleukin-6 (Il-6), interleukin-1b (Il-1b), monocyte chemoattrac-
tant protein 1 (Mcp1), and fibrosis-related genes. In immunized mice, KCs were smaller
and showed fewer cholesterol crystals compared with nonimmunized mice. Conclusion:
Antibodies to oxLDL play an important role in the pathogenesis of NASH. Therefore, the
potential of phosphorylcholine-based vaccination strategies as a novel tool for the preven-
tion and therapy of NASH should be tested in the future. (HEPATOLOGY 2012;56:894-903)
N
onalcoholic fatty liver disease (NAFLD) is a
condition ranging from benign lipid accumu-
lation in the liver (steatosis) to steatosis com-
bined with inflammation. The latter is referred to as
nonalcoholic steatohepatitis (NASH). NASH is consid-
ered as the hepatic component of the metabolic syn-
drome. Estimates from the United States are that
5.7%-17% of all adults have NASH, while 17%-33%
of Americans suffer from NAFLD.1,2 As obesity and
insulin resistance reach epidemic proportions in indus-
trialized countries, the prevalence of both NAFLD and
NASH is increasing. NAFLD is therefore a major
health hazard.3 Steatosis alone is considered a relatively
benign and reversible condition. However, the transi-
tion toward NASH represents a key step in the patho-
genesis, as it sets the stage for the development of
fibrosis, cirrhosis, and liver cancer. Although the mech-
anisms leading to steatosis are well described, little is
known about the actual risk factors that drive hepatic
inflammation during the progression toward NASH.
Consequently, therapeutic options are limited. There-
fore, knowledge about the events that lead to hepatic
inflammation is of great importance for the diagnosis
and treatment of NASH.
Recently, we demonstrated that deletion of scav-
enger receptors (SRs) CD36 and SR-A in
Abbreviations: apo, apolipoprotein; Col1A1, collagen type 1A1; FFA, free fatty acid; HFC, high-fat, high-cholesterol; IgG, immunoglobulin G; IgM,
immunoglobulin M; Il-1b, interleukin-1b, Il-6, interleukin-6; KC, Kupffer cell; LDL, low-density lipoprotein; Ldlr/, low-density lipoprotein receptor; Mcp1,
monocyte chemoattractant protein 1; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; oxLDL, oxidized low-density lipoprotein; PC,
phosphorylcholine; RLU, relative light unit; SR, scavenger receptors; TG, triglyceride; Tnf, tumor necrosis factor; Tgf-b, transforming growth factor b.
From the Departments of 1Molecular Genetics, 2Pathology, 3Molecular Cell Biology, Electron Microscopy Unit, and 4Surgery, Maastricht University, the Netherlands;
the Departments of 5Microbiology and 6Departments of Pediatrics, The University of Alabama at Birmingham, Birmingham, AL; the 7Department of Pathology and
Medical Biology, University Medical Center Groningen, Groningen, the Netherlands; the 8Department of Laboratory Medicine, Medical University of Vienna, Vienna,
Austria; and the 9Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria.
Received September 3, 2011; accepted February 6, 2011.
894
hematopoietic cells reduced hepatic inflammation.4 In
addition to uptake of modified lipids, scavenger recep-
tors are involved in many other inflammatory path-
ways. These pathways include cellular adhesion, innate
immune responses, and phagocytosis of apoptotic
cells.5 Based on the analogy between mechanisms for
atherosclerosis and NASH, it is likely that the recogni-
tion of oxidized low-density lipoprotein (oxLDL) by
Kupffer cells (KCs), rather than other pathways, is the
actual trigger for scavenger receptor-mediated inflam-
mation. Therefore, we hypothesized that hepatic
inflammation is triggered by the recognition of oxLDL
by KCs.
It has recently been shown that the levels of immu-
noglobulin M (IgM) autoantibodies to modified LDL
are inversely correlated with atherosclerosis.6-8 Oxida-
tion-specific epitopes present in oxLDL are major tar-
gets of natural IgM antibodies.9 These antibodies arise
spontaneously without prior infection or immune
exposure and mainly consist of the IgM isotype.10
They are produced by innate-like B-1 cells and provide
a first line of defense against bacterial and viral patho-
gens.11,12 In addition, natural IgM antibodies play an
important role in providing housekeeping functions by
protecting from the accumulation of biological waste,
such as oxLDL.10 Upon oxidation of LDL, reactive
oxidation products from phospholipids retain the
intact phosphorylcholine (PC) headgroup, which
becomes available for immune recognition. These PC
headgroups represent one of many so-called oxidation-
specific epitopes and are found on the outer side of
the membrane of oxLDL.13 A panel of monoclonal au-
toantibodies directed to epitopes of oxLDL was cloned
from the spleens of apolipoprotein E (apoE/)
mice.14 In particular, one immunodominant clonotypic
set of IgM autoantibodies was identified, EO6, which
was shown to specifically bind to the PC moiety of
oxidized PC-containing phospholipids, such as those
present in oxLDL.13 EO6 antibodies were found to be
identical to the natural T15 antibodies, which are
germline-encoded natural antibodies exclusively derived
from B-1 cells. These T15 antibodies protect mice
against Streptococcus pneumonia infections, because PC
is also present in the capsular polysaccharide of the cell
wall of this bacterium. Based on this molecular mim-
icry, immunization of low-density lipoprotein receptor
(Ldlr/) mice with heat-killed S. pneumonia resulted
in higher serum titers of anti-oxLDL IgM antibodies
and decreased atherosclerosis.15 These findings suggest
that anti-oxLDL antibodies directed to the PC group
present on oxLDL possibly inhibit the recognition of
oxLDL by macrophage SRs such as CD36.
The aim of the current study was to determine
whether oxLDL is causally involved in the pathogene-
sis of NASH. For this purpose, Ldlr/ mice were
used as a well-recognized model mimicking the human
lipoprotein metabolism with high fidelity and is there-
fore also extremely useful to investigate the physiologi-
cal triggers for hepatic inflammation, which can
already develop upon short-term treatment with a
high-fat, high-cholesterol (HFC) diet.16 These mice
were immunized with heat-inactivated pneumococci to
investigate whether anti-oxLDL antibodies have a pro-
tective effect on NASH. Supporting our hypothesis,
immunized Ldlr/ mice showed reduced hepatic
inflammation compared to non-immunized mice. These
data demonstrate the importance of antibodies to
oxLDL in the pathogenesis of NASH. Therefore, the
potential of PC-based vaccination strategies as novel
tool for the prevention and therapy of NASH should
be tested in the future.
Materials and Methods
Preparation Immunogen. For immunization, the
heat-inactivated R36A strain of S. pneumoniae (Bir-
mingham, AL) was used, still bearing the PC head-
group epitope similar to oxLDL. Colonies of the
R36A strain were harvested at mid-log phase after
incubation at 37C on blood agar plates and trans-
ferred to Todd-Hewitt plus 0.5% yeast broth. The
mid-log phase is characterized by an opitcal density
(OD) value of 0.425 to 0.45 at 600 nm. S. pneumo-
niae was heat-inactivated at 60C for 30 minutes;
afterward, no colonies of this suspension were detected
on blood agar plates. For freezer stocks of strain
R36A, small aliquots of S. pneumoniae at mid-log
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density were harvested and suspended in Todd-Hewitt
plus 80% sterile glycerol and stored at 80C.17
Mice, Immunization, and Diet. Ldlr/ mice on a
C57BL/6 background were housed under standard
conditions and had access to food and water ad libi-
tum. Experiments were performed according to Dutch
laws and were approved by the Animal Experiment
Committee of Maastricht University.
The immunization protocol started in 12-week-old
female mice fed a normal chow diet. Mice were
divided into four groups (n ¼ 10 for each group) and
received the equivilant of 108 colony-forming units of
the heat-killed pneumococcal immunogen emulsified
in 200 lL sterile 0.9% NaCl for the primary subcuta-
neous immunization, subsequently three intraperito-
neal booster immunizations were administered every 2
weeks.15 The control group received an NaCl injection
only. After immunization, the mice were given normal
chow, the control group, or a HFC diet, the experi-
mental group, for 3 weeks. Blood from the tail vein
was collected after the dietary period and mice were
then sacrificed by cervical dislocation. Liver tissue was
isolated and snap-frozen in liquid nitrogen and stored
at 80C or fixed in 4% formaldehyde/PBS. The
collection of blood and specimens, the biochemical
determination of lipids in plasma and the liver, liver
histology, alanine aminotransferase, RNA isolation,
complementary DNA synthesis and quantitative poly-
merase chain reaction and auto-antibody titers against
IgG and IgM antibodies to CuOx-LDL and malon-
dialdehyde-LDL have been described extensively.4
Immune complex measurements were performed as
described.15 Briefly, circulating immune complexes
were determined by a capture assay in which a polyco-
lonal antibody specific for murine apoB100 was coated
on microtiter wells at 5 lg/mL in phosphate-buffered
saline. Individual mouse sera (1:100) were added to
the wells and incubated for 1 hour at room tempera-
ture. IgM bound to the captured apoB-containing
particles was detected using an alkaline phosphatase–
conjugated goat anti-mouse IgM antibody by chemilu-
minescent enzyme-linked immunosorbent assay. The
amount of IgM bound to the captured LDL was then
normalized for the amount of captured apoB and
expressed as a ratio of IgM counts (relative light units/
100 ms) to apoB100 counts (relative light units/100
ms) or IgM/apoB.
Electron Microscopy. A detailed overview about the
postfixation, embedding, cutting, and type of electron
microscope has been described.16 To stain the KC
lysosomes, acid phosphatase enzyme cytochemistry was
performed. Small wedge biopsies of the liver were per-
fused by syringe injection with ice-cold 2% purified
glutaraldehyde in 0.1 M cacodylater buffer (pH 7.4)
for 15 minutes. The wedge biopsies were cut into
small pieces and kept in 0.1 M cacodylate buffer plus
7.5% sucrose at 4C until further processing; the
buffer solution was refreshed weekly. The samples were
frozen for 1 hour at 30C whereafter 50-lm-thick
cryosections were made. These sections were incubated
according to the cerium-based method of Robinson
and Karnovsky for the localization of acid phospha-
tase.32 After incubation, the sections were washed two
times in 0.1 M cacodylate buffer supplemented with
5% sucrose, refixed in 3% glutaraldehyde in cacodylate
buffer for 1 hour and rinsed overnight in veronal ace-
tate buffer (pH 7.4, 4C). The sections were then
postfixed for 30 minutes in 2% osmium tetroxide in
veronal buffer plus 4% sucrose and then routinely
processed for embedding in epon.
Statistical Analysis. Data were statistically analyzed
by performing two-tailed nonpaired t tests using
GraphPad Prism version 4.03 for Windows. Data are
expressed as the mean 6 SEM and were considered
significant at P < 0.05.
Results
Increased IgM Antibody Titers Against Modified
LDL After Immunization with Heat-Inactivated
Pneumococci. To determine whether IgM autoanti-
bodies to oxLDL have a protective effect on liver
inflammation, mice were immunized for 9 weeks with
heat-inactivated pneumococci, known to induce high
anti-oxLDL IgM titers dominated by T15-idiotypic
IgM. To induce NASH, the mice received an HFC
diet during the last 3 weeks. Total body weight and
the ratio of liver weight to total body weight were not
significantly different between the different groups
(Supporting Fig. 1). Immunization of Ldlr/ mice
with heat-inactivated pneumococci resulted in a strong
increase in IgM titers to oxLDL (Fig. 1A,B). Only
weak but significant IgG responses were observed, con-
sistent with previous reports that pneumococcal immu-
nizations induce an IgM-dominated thymus-independ-
ent type-2 response highly specific for PC (Fig. 1C,D).
The levels of circulating IgM/apoB immune complexes
did not differ between the groups, likely indicating
efficient clearance of oxLDL (Supporting Fig. 2).
No Difference in Liver Lipid Levels Between
Immunized and Nonimmunized Ldlr2/2 Mice After
3 Weeks of HFC Diet. To investigate liver lipid levels
in hyperlipidemic mice with or without immunization,
biochemical assessment of liver cholesterol, triglycerides
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(TGs), and free fatty acids (FFAs) was performed
(Fig. 2A). After 3 weeks on an HFC diet, a clear
increase in all liver lipid levels was observed compared
with mice on a chow diet. Liver lipid levels did not dif-
fer between immunized and nonimmunized Ldlr/
mice on the HFC diet. Mice on the chow diet showed
a small increase in liver lipid levels after immunization
when compared with nonimmunized Ldlr/ mice. Oil
red O and hematoxylin and eosin staining confirmed
the biochemical liver lipid measurements (Fig. 2B-E
and Supporting Fig. 3).
Decreased Plasma Cholesterol in Immunized
Ldlr2/2 Mice on an HFC Diet Compared with Con-
trol Mice. The effect of immunization on plasma lip-
ids was assessed by measuring the levels of plasma cho-
lesterol, TGs, and FFAs. After feeding on the HFC
diet, a significant increase was observed for all plasma
lipids compared with mice on a chow diet. Interest-
ingly, plasma cholesterol was reduced in immunized
Ldlr/ mice compared to nonimmunized mice on an
HFC diet. Plasma TGs and FFAs did not differ
between the groups following an HFC diet. On chow
diet, plasma lipid levels did not differ between the
groups (Fig. 3).
Decreased Hepatic Inflammation in Ldlr2/2 Mice
Immunized with Heat-Inactivated Pneumococci. To
determine whether immunization of Ldlr/ mice
with heat-inactivated pneumococci affects hepatic
inflammation, liver sections were stained for the
inflammatory cell markers Mac-1 (infiltrated macro-
phages and neutrophils), NIMP (neutrophils), and
CD3 (T cells). As shown in Fig. 4A, the number of
infiltrated macrophages, neutrophils, and T cells was
lower in immunized Ldlr/ mice compared with
nonimmunized mice after feeding on an HFC diet.
These data on cell infiltration are confirmed by hema-
toxylin and eosin staining (Supporting Fig. 3). More-
over, the normal chow diet induced a significant
increase in the number of neutrophils in immunized
chow-fed mice compared with nonimmunized mice.
Representative histological pictures of the Mac-1 stain-
ing for all four experimental groups are shown in Figure
4B-E. Further confirming the reduced hepatic inflam-
mation in immunized Ldlr/ mice on the HFC diet,
gene expression analysis showed a significant decrease in
the inflammatory markers tumor necrosis factor (Tnf),
interleukin-1b (Il-1b), interleukin-6 (Il-6), and mono-
cyte chemoattractant protein 1 (Mcp1) in livers of
immunized Ldlr/ mice on an HFC diet compared
with nonimmunized mice (Fig. 4F). However, hepatic
inflammation in Ldlr/ mice on an HFC diet after
immunization was still higher than chow-fed immu-
nized mice according to the inflammatory markers Tnf,
Il-1b, and Mcp1. The presence of elevated aminotrans-
ferases in plasma-like alanine aminotransferase did not
differ between the different groups (Supporting Fig. 4).
After 3 Weeks of HFC Diet, Immunization
Prevented Expression of Fibrosis-Related Genes in
Ldlr2/2 Mice. Fibrosis is considered an advanced stage
of NASH. Collagen staining (sirius red) was performed
Fig. 1. IgM autoantibodies in mice that
received pneumococcal immunization. (A-D)
IgM and IgG antibodies against oxLDL (CuOx
and PC-BSA) were measured in plasma of
pneumococci-immunized (n ¼ 10) and con-
trol (n ¼ 10) mice at a dilution of 1:200,
respectively. Data are expressed as relative
light units (RLU)/100 ms and were triplicate
determinations. *P < 0.05; **P < 0.01;
***P < 0.001.
HEPATOLOGY, Vol. 56, No. 3, 2012 BIEGHS ET AL. 897
to determine the degree of fibrosis. No differences were
observed between the experimental groups after 3 weeks
of an HFC diet (Fig. 5A), which is probably related to
the short duration of the HFC diet. However, gene
expression analysis for collagen type 1A1 (Col1A1) and
transforming growth factor b (Tgf-b) demonstrated that
the messenger RNA levels of these fibrogenic genes
were lower in immunized mice compared with nonim-
munized mice on an HFC diet (Fig. 5B).
Decreased Foamy Appearance of KCs in Immu-
nized Ldlr2/2 Mice on an HFC Diet. Immunohisto-
chemistry for CD68 was performed to characterize the
KCs. Scoring of the CD68 positive sections revealed a
reduction in size of foamy KCs in immunized Ldlr/
mice compared with nonimmunized mice on an HFC
diet (Fig. 6A-C). Gene expression of Cd68 was
reduced in the immunized Ldlr/ mice compared
with nonimmunized mice on an HFC diet (Fig. 6B).
Fig. 2. Liver lipid levels. (A) Liver cholesterol, TGs, and FFAs after chow and 3 weeks of an HFC diet. (B-E) Oil red O staining after 3 weeks
of an HFC diet in (B,D) nonimmunized (C,E) and immunized Ldlr/ mice after (B,C) chow and (D,E) 3 weeks of feeding on an HFC diet, respec-
tively. Asterisks indicate significant difference from nonimmunized mice on a chow diet. *P < 0.05; **P < 0.01; ***P < 0.001.
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Electron microscopy of KCs confirmed the differences
in size of the KCs between immunized and nonimmu-
nized Ldlr/ mice, and showed that the immunized
mice on an HFC diet had less lysosomal cholesterol
accumulation and cholesterol crystals compared with
nonimmunized mice (Fig. 6D).
Discussion
Until now, the actual risk factors that drive hepatic
inflammation during the progression to NASH were
unknown. To determine whether oxLDL is causally
involved in the pathogenesis of NASH, serum anti-
oxLDL IgM antibody levels were increased by immu-
nizing Ldlr/ mice with heat-inactivated pneumo-
cocci, which dramatically decreased hepatic inflamma-
tion. These data point toward oxLDL as a trigger for
hepatic inflammation. Furthermore, our data suggest
that PC-based vaccination strategies could be the basis
for a vaccination protocol for NASH therapy. How-
ever, the long-term consequences of immunization are
unknown at the moment and should be tested in the
future.
SR-mediated uptake of oxidized lipoproteins by
macrophages sets off a cascade of proinflammatory
events leading to the initiation of the inflammatory
response. oxLDL is phagocytosed by macrophages via
binding of the oxPC molecules present in oxLDL to
macrophage SRs and results in foam cells.18,19 Further-
more, CD36 has been implicated in inflammatory sig-
naling induced by oxLDL.20 Previously, we have
shown that both CD36 and SR-A play an important
role in diet-induced NASH.4 Because scavenger recep-
tors have a wide spectrum of functions,21-23 it is not
clear whether the recognition of modified lipoproteins
is the actual trigger for hepatic inflammation during
NASH. Our data demonstrate for the first time that
inflammation is reduced in the livers of pneumococci-
immunized mice. These results are in line with earlier
findings demonstrating decreased atherosclerotic lesion
formation after pneumococcal immunization.15 Simi-
larly, apoE/ mice immunized with PC, one of the
epitopes of anti-oxLDL autoantibodies present in
oxLDL but also in the CPS of S. pneumoniae, demon-
strated an increase in anti-oxLDL autoantibodies to-
gether with a reduction in atherosclerotic lesions.24
Several in vitro studies suggest that the induced IgM
antibodies against oxLDL prevent binding and uptake
of oxLDL by macrophages and/or neutralize its proin-
flammatory signaling.11,15,25,26 Indeed, the inflamma-
tory process associated with atherosclerotic plaque for-
mation is linked to the cytotoxicity and macrophage
chemo-attractivity of oxLDL. Moreover, oxLDL is
thought to be an atherogenic factor, because its uptake
by macrophages results in the formation of foam cells,
the hallmark cells of atherosclerotic lesions.18,19,27 Our
data provide evidence for similar mechanisms between
atherosclerosis and NASH. Thus, the reduced inflam-
mation in mice in which the SRs on hematopoietic
cells had been deleted is likely to be related to the
reduced recognition of oxLDL by KCs.
Interestingly, plasma cholesterol levels were signifi-
cantly reduced in our immunized Ldlr/ mice. Previ-
ously, it was shown that anti-oxLDL antibodies
directed to the PC group present on oxLDL inhibit
the recognition of oxLDL by macrophage SRs.28 We
speculate that the formed immune complexes contain-
ing both LDL and oxLDL particles may be cleared
faster by alternative pathways, as this is the case for
IgM mediating apoptotic cell clearance. However,
measurements of IgM/apoB immune complexes indi-
cated that there were no differences between our
groups of Ldlr/ mice, also suggesting that the
induced IgM mediate their protective effect by directly
neutralizing the proinflammatory effects of oxLDL.
These findings are in line with Binder et al.,15 who
Fig. 3. Plasma lipid levels. Plasma cholesterol, TGs, and FFAs after a chow diet and 3 weeks of an HFC diet in nonimmunized and immunized
Ldlr/ mice. Asterisks indicate significant difference from nonimmunized mice on a chow diet. *P < 0.05; **P < 0.01; ***P < 0.001.
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demonstrated that under these conditions, no differen-
ces in immune complexes were observed. It is possible
that the protective effect of these antibodies in vivo is
further enhanced via a reduction in plasma cholesterol
levels, since plasma cholesterol levels are an important
trigger for hepatic inflammation.16
NASH patients are often associated with high levels
of lipid peroxidation products such as those present in
Fig. 4. Parameters of hepatic inflammation. (A) Liver sections were stained for infiltrated macrophages and neutrophils (Mac-1), neutrophils
(NIMP), and T cells (CD3) and counted. (B-E) Representative images of Mac-1 staining (magnification 200) after feeding on a chow (B,C) and
an HFC diet (D,E) in nonimmunized (B,D) and immunized (C,E) Ldlr/ mice, respectively. (F) Gene expression analysis for Tnf, Il6, Il1b, and
Mcp1. Asterisks indicate significant difference from nonimmunized mice on a chow diet. *P < 0.05; **P < 0.01; ***P < 0.001.
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Fig. 5. Parameters of hepatic fibrosis. (A) Quantification of sirius red (collagen) after 3 weeks of an HFC diet. Livers were quantified as mini-
mally, mildly, or moderately positive for collagen around and in between the blood vessels of the liver. (B) Gene expression analysis of the fibro-
sis markers, collagen (Col1A1) and Tgf-b. Asterisks indicate significant difference from nonimmunized mice on a chow diet. *P < 0.05; **P <
0.01; ***P < 0.001.
Fig. 6. Foamy KCs. (A) Liver sections were stained for CD68 (KCs) and scored for the level of foamy appearance: 1 (mild foamy appearance)
to 3 (severe foamy appearance). Mean scores were calculated from six microscopic views. (B) Gene expression analysis of the KC activation
marker CD68. (C) Representative images of liver sections stained for CD68 for Ldlr/ mice on a chow diet without and with immunization and
for Ldlr/ mice on an HFC diet without and with immunization, respectively (magnification 200). (D) Electron microscopy of foamy KCs. Acid
phosphatase staining indicating the lysosomes of the KCs in nonimmunized and immunized Ldlr/ mice on an HFC diet. Asterisks indicate sig-
nificant difference from nonimmunized mice on a chow diet. *P < 0.05; ***P < 0.001.
HEPATOLOGY, Vol. 56, No. 3, 2012 BIEGHS ET AL. 901
oxLDL. Therefore, it has been suggested that the
elevated levels of lipid peroxidation might make an
important contribution to the pathogenesis of
NASH.29,30 In the literature, it is demonstrated that
the presence of immune responses toward lipid peroxi-
dation products can be a predictor of progression of
NAFLD.31 In addition, it was demonstrated that oxi-
dized phosphatidylcholines were found predominantly
in steatotic hepatocytes and macrophages/KCs and
were more abundant in NAFLD/NASH livers than in
normal control livers.32 Moreover, we have shown that
NASH patients display increased hepatic myeloperoxi-
dase activity, which is also associated with lipid peroxi-
dation.33 The role of oxidative stress as a key factor
contributing to hepatic injury in patients with
NASH34,35 has been underlined by a study with vita-
min E therapy of nondiabetic NASH patients.36
Because fibrosis is one of the later consequences of
NASH, we investigated the effect of immunization
with heat-inactivated pneumococci on hepatic fibrosis.
Gene expression of fibrosis-related genes was decreased,
yet not confirmed by sirius red staining. This is prob-
ably due to the short period of 3 weeks on an HFC
diet, because Ldlr/ mice only develop fibrosis after 3
months on a mild atherogenic diet.4 However, we
report for the first time that uptake of oxLDL is asso-
ciated with fibrogenesis in vivo. In line with these
observations, a study by Kang et al. demonstrated that
oxLDL can activate hepatic stellate cells in vitro.37
These findings indicate a crucial role for oxLDL in the
fibrogenic process.
As expected, immunized mice on an HFC diet
showed decreased foamy KCs compared with nonim-
munized mice. This reduction in size is probably due
to decreased plasma cholesterol levels, as the size of
the foamy KCs is not always correlated with the
inflammatory state of the liver.4,16 Overloading of
macrophages with oxLDL was shown to lead to the
formation of cholesterol monohydrate crystals.38 In
line with these findings, we showed that after immuni-
zation with heat-inactivated pneumococci, KCs were
less foamy, had less lysosomal cholesterol accumulation
and therefore also less cholesterol crystals. These data
indicate that the increased cholesterol accumulation
inside KCs, together with the crystallization, is linked
to hepatic inflammation.
To date, no therapy for NASH is available. Our
novel data in mice suggest that future research should
focus on oxLDL as a trigger for NASH. Therefore, the
potential of PC-based vaccination strategies to be used
as a novel tool for the prevention and therapy of
NASH should be tested in the future.
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